Photonics
Partnership website: https://www.photonics21.org/
Photonics (light based technologies) is an essential building block for the digital transformation and for a green and healthy future in Europe. The main objectives are to strengthen the photonics ecosystem along the value chain, support diffusion of photonics technologies and contributes to growth and jobs and raise competitiveness.
By 2030 Europe will have maintained leadership in core and emerging photonic technologies.
The European Technology Platform Photonics21 represents the photonics community of industry and research organisations. Jointly with the European Commission our members develop and implement a common photonics strategy in a Horizon Europe Public Private Partnership (PPP) to spur growth and jobs in Europe.
Contact
Partners: Photonics21: secretariat@photonics21.org
What are partnerships?
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
How to use partnerships?
-
orientation
Partnerships publish strategic documents, e.g. outlining the main research and innovation challenges or key focus points. -
networking
Partnerships often organise events, such as info days, brokerage events, etc. Meet potential partners and learn about the nuances that are not visible in the official documents. -
ecosystem analysis
Partnerships typically have an advisory board, and publish impact studies of previous actions. These are good sources of information to uncover the main R&D&I players in the domain. -
steering the agenda
Partnerships collaborate with the EC on outlining the strategy and the future funding opportunities in their domain, based on input from industry, academia, and other stakeholders.
Testimonial
Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
